Jane Street’s InMed Pharmaceuticals INM Stock Holding History

Jane Street’s Portfolio INM Stock Details INM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,978	Closed	-$12.7K	–	12240
2025 Q4	$12.7K	Buy	+11,978	New	+$19.9K	﹤0.01%	10803

Other funds holding INM

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PWMG

Private Wealth Management Group Princeton, New Jersey $431M AUM 20.62% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Jane Street's INM Position: Q1 2026 in Review

Jane Street sold out of InMed Pharmaceuticals (INM) in Q1 2026, closing a stake of 11,978 shares — an estimated $12.7K sold.

Jane Street first reported a position in INM in Q4 2025 and held it in 1 quarter. The position peaked at $12.7K in Q4 2025. 9 funds tracked by Wall St. Rank hold INM as of Q1 2026.

Jane Street reported no remaining InMed Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Jane Street sold 11,978 InMed Pharmaceuticals shares in Q1 2026, an estimated $12.7K.
Jane Street first reported a position in InMed Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Jane Street's InMed Pharmaceuticals position peaked at $12.7K in Q4 2025.
9 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.